Cargando…

Prophylactic Therapy Response in Children with Abdominal Migraine: A Single Centre Experience in Oman

PURPOSE: Abdominal migraine (AM) is a very common functional gastrointestinal disorder in children. This study reports the clinical features and response of AM to prophylactic treatment in children. METHODS: This retrospective study was conducted between January 2010 and December 2019 at the Royal H...

Descripción completa

Detalles Bibliográficos
Autores principales: Al Lawati, Tawfiq Taki, Saadah, Omar I., al Riyami, Ruwaina, al Yarubi, Zuwaina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Society of Pediatric Gastroenterology, Hepatology and Nutrition 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8958052/
https://www.ncbi.nlm.nih.gov/pubmed/35360376
http://dx.doi.org/10.5223/pghn.2022.25.2.121
_version_ 1784676866947284992
author Al Lawati, Tawfiq Taki
Saadah, Omar I.
al Riyami, Ruwaina
al Yarubi, Zuwaina
author_facet Al Lawati, Tawfiq Taki
Saadah, Omar I.
al Riyami, Ruwaina
al Yarubi, Zuwaina
author_sort Al Lawati, Tawfiq Taki
collection PubMed
description PURPOSE: Abdominal migraine (AM) is a very common functional gastrointestinal disorder in children. This study reports the clinical features and response of AM to prophylactic treatment in children. METHODS: This retrospective study was conducted between January 2010 and December 2019 at the Royal Hospital in the Sultanate of Oman. This study included children aged ≤ 13 years with a diagnosis of AM based on the Rome IV criteria for functional diagnoses. Clinical, demographic, and treatment data were collected. RESULTS: Seventy-four children were identified, of which 43 were eligible for inclusion in this study. The median age at the onset of symptoms was 7 years (range, 2–12 years). The most frequent symptoms were headache (81.4%), nausea (79.1%), and vomiting (72.1%). Of the total cohort, 46.5%, 23.3%, and 6.9% received riboflavin, pizotifen, and propranolol monotherapy, respectively. Combination therapy was also used; 16.3% of children received pizotifen and propranolol, 4.7% received riboflavin and pizotifen, and 2.3% received riboflavin and propranolol. Patients treated with propranolol monotherapy showed 100% clinical improvement and those treated with riboflavin or pizotifen monotherapy showed 90% clinical improvement. Response to combination therapy with pizotifen and propranolol was 71.4%, and with riboflavin and pizotifen was 100%. In addition, treatment response was significantly associated with the presence of vomiting (p=0.039). CONCLUSION: We found a favorable response to various modalities and combination treatments with riboflavin, pizotifen, and propranolol in children with AM. In addition, the presence of vomiting may predict treatment response.
format Online
Article
Text
id pubmed-8958052
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher The Korean Society of Pediatric Gastroenterology, Hepatology and Nutrition
record_format MEDLINE/PubMed
spelling pubmed-89580522022-03-30 Prophylactic Therapy Response in Children with Abdominal Migraine: A Single Centre Experience in Oman Al Lawati, Tawfiq Taki Saadah, Omar I. al Riyami, Ruwaina al Yarubi, Zuwaina Pediatr Gastroenterol Hepatol Nutr Original Article PURPOSE: Abdominal migraine (AM) is a very common functional gastrointestinal disorder in children. This study reports the clinical features and response of AM to prophylactic treatment in children. METHODS: This retrospective study was conducted between January 2010 and December 2019 at the Royal Hospital in the Sultanate of Oman. This study included children aged ≤ 13 years with a diagnosis of AM based on the Rome IV criteria for functional diagnoses. Clinical, demographic, and treatment data were collected. RESULTS: Seventy-four children were identified, of which 43 were eligible for inclusion in this study. The median age at the onset of symptoms was 7 years (range, 2–12 years). The most frequent symptoms were headache (81.4%), nausea (79.1%), and vomiting (72.1%). Of the total cohort, 46.5%, 23.3%, and 6.9% received riboflavin, pizotifen, and propranolol monotherapy, respectively. Combination therapy was also used; 16.3% of children received pizotifen and propranolol, 4.7% received riboflavin and pizotifen, and 2.3% received riboflavin and propranolol. Patients treated with propranolol monotherapy showed 100% clinical improvement and those treated with riboflavin or pizotifen monotherapy showed 90% clinical improvement. Response to combination therapy with pizotifen and propranolol was 71.4%, and with riboflavin and pizotifen was 100%. In addition, treatment response was significantly associated with the presence of vomiting (p=0.039). CONCLUSION: We found a favorable response to various modalities and combination treatments with riboflavin, pizotifen, and propranolol in children with AM. In addition, the presence of vomiting may predict treatment response. The Korean Society of Pediatric Gastroenterology, Hepatology and Nutrition 2022-03 2022-03-10 /pmc/articles/PMC8958052/ /pubmed/35360376 http://dx.doi.org/10.5223/pghn.2022.25.2.121 Text en Copyright © 2022 by The Korean Society of Pediatric Gastroenterology, Hepatology and Nutrition https://creativecommons.org/licenses/by-nc/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Al Lawati, Tawfiq Taki
Saadah, Omar I.
al Riyami, Ruwaina
al Yarubi, Zuwaina
Prophylactic Therapy Response in Children with Abdominal Migraine: A Single Centre Experience in Oman
title Prophylactic Therapy Response in Children with Abdominal Migraine: A Single Centre Experience in Oman
title_full Prophylactic Therapy Response in Children with Abdominal Migraine: A Single Centre Experience in Oman
title_fullStr Prophylactic Therapy Response in Children with Abdominal Migraine: A Single Centre Experience in Oman
title_full_unstemmed Prophylactic Therapy Response in Children with Abdominal Migraine: A Single Centre Experience in Oman
title_short Prophylactic Therapy Response in Children with Abdominal Migraine: A Single Centre Experience in Oman
title_sort prophylactic therapy response in children with abdominal migraine: a single centre experience in oman
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8958052/
https://www.ncbi.nlm.nih.gov/pubmed/35360376
http://dx.doi.org/10.5223/pghn.2022.25.2.121
work_keys_str_mv AT allawatitawfiqtaki prophylactictherapyresponseinchildrenwithabdominalmigraineasinglecentreexperienceinoman
AT saadahomari prophylactictherapyresponseinchildrenwithabdominalmigraineasinglecentreexperienceinoman
AT alriyamiruwaina prophylactictherapyresponseinchildrenwithabdominalmigraineasinglecentreexperienceinoman
AT alyarubizuwaina prophylactictherapyresponseinchildrenwithabdominalmigraineasinglecentreexperienceinoman